Most hair loss can be diagnosed based on history, examination and trichoscopy. Occasionally, however, a scalp biopsy is necessary to clarify what is occurring at the follicular level. This article explains when a biopsy is indicated, how the site is chosen, what the procedure involves, what pathologists look for under the microscope, and how biopsy findings are integrated into a final diagnosis.
![[headshot]](https://cdn.prod.website-files.com/68207da82e5b8c350c67932f/68c6a7436a552c0fe87a4da7_Screenshot%202024-11-27%20at%2011.38.11.png)

A scalp biopsy is a small sample of skin used when the cause of hair loss remains unclear after history, examination and trichoscopy. It is not needed for straightforward male or female pattern hair loss, but becomes valuable when there is suspicion of scarring alopecia, unexplained diffuse shedding, mixed patterns, poor treatment response, or associated systemic or autoimmune features. The biopsy helps distinguish scarring from non-scarring conditions, assess follicle numbers and growth phases, and identify the type and location of inflammation. Correct site selection and timing are crucial to avoid misleading results. When interpreted alongside clinical findings, a biopsy can clarify diagnosis, guide targeted treatment and prevent years of misdirected management.
A scalp biopsy is a small sample of skin, usually 4 mm in diameter, taken under local anaesthetic. It includes the full thickness of the scalp skin, the hair follicles, and a portion of the underlying subcutaneous fat.
The sample is processed and examined by a dermatopathologist. The aim is not simply “to see if there is hair loss”. It is to:
In many cases (for example, classic male pattern hair loss or straightforward postpartum shedding), a biopsy is not necessary. But in more complex or atypical presentations, biopsy can prevent years of uncertainty or misdirected treatment.
A biopsy is considered when the answer to “what is causing this hair loss?” remains uncertain after careful history, examination, and trichoscopy.
If there are signs that follicles are being permanently destroyed, such as:
then a biopsy is usually recommended. This is because scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, CCCA, discoid lupus, folliculitis decalvans, dissecting cellulitis) require early, targeted anti-inflammatory treatment. Additionally, diagnosis based on appearance alone can be challenging, and histology helps decide which immunomodulatory regimen is most appropriate.
A biopsy may also be suggested when:
In these situations, a biopsy can confirm miniaturisation typical of androgenetic alopecia, detect superimposed inflammatory changes indicative of scarring disease, or reveal alopecia areata incognita when patches are not obvious.
Where an apparently straightforward diagnosis has been treated appropriately but the response is absent or the progression is faster than expected, a biopsy may be used to check whether a second process (for example, early scarring) has been missed.
In children, biopsy is used more sparingly but may be considered when:
Overall, a biopsy is not always necessary; it is a tailored decision driven by diagnostic uncertainty or concern about irreversible disease.
Sampling error is a major reason biopsies can mislead. Choosing the correct site is therefore necessary.
In suspected scarring alopecia, the ideal site is at the active edge of a lesion, where hair is still present, along with redness, scale, or symptoms.
Taking a biopsy from the completely bald centre of a long-standing scar may only show end-stage fibrosis, making it hard to distinguish between different scarring conditions.
In patchy alopecia areata, a sample from the border of a patch will often capture both affected and relatively unaffected follicles, providing more information about the inflammatory process.
The location may also be chosen based on the suspected diagnosis:
Many hair specialists prefer to take two 4 mm punch biopsies from adjacent sites: one processed with vertical sections, and the other with horizontal (transverse) sections. This “double-biopsy” approach allows assessment of both epidermal and dermal architecture along a vertical axis, and follicular counts and cycling in horizontal planes.
When resources are limited, a single punch processed with step-serial horizontal sections can still yield a great deal of information.
A scalp biopsy is generally done in an outpatient setting and takes 10–20 minutes.
Roughly, the steps are:
Patients can usually go home immediately afterwards. Mild tenderness for a day or two is common. Sutures, if used, are typically removed after 7–10 days. The resulting scar is:
Risks include bleeding, infection, poor wound healing, altered sensation or, rarely, keloid formation, particularly in those prone to hypertrophic scarring. These risks are low when the procedure is done properly and after appropriate counselling.
Once in the laboratory, the biopsy is processed and sectioned. The dermatopathologist examines a range of features that together create a histological “profile” of the alopecia.
Key elements include:
This fundamental distinction often underpins urgent treatment decisions.
Horizontal sections are particularly useful for:
Typical patterns:
The nature of the inflammatory infiltrate and where it sits relative to the follicle are highly informative.
Examples:
The type (lymphocytic, neutrophilic, mixed, granulomatous) and the level targeted (bulb, isthmus, infundibulum, dermo–epidermal junction) are central to classifying scarring alopecias.
Vertical sections show:
These provide context to follicular findings and can point towards specific conditions (for example, thickened basement membrane and mucin in lupus).
Without going into full textbook detail, a few characteristic patterns are worth noting.
These patterns, combined with clinical and trichoscopic data, guide diagnosis and treatment choices.
A biopsy report is not interpreted in isolation. The clinician assesses it alongside the patient’s history of onset, progression and symptoms, examination and trichoscopy findings, and any relevant laboratory results.
The report may confirm a suspected diagnosis (for example, AGA versus chronic TE), reveal a scarring process that was not clinically apparent, or highlight more than one process (for example, androgenetic alopecia with superimposed lichen planopilaris).
From there, management can be adjusted:
Occasionally, biopsy results are non-specific (for example, “end-stage scarring alopecia” without a clear cause) if taken from late, burnt-out lesions. This reinforces the importance of timing and site selection.
If a biopsy is proposed, it is reasonable to ask:
A good clinician will welcome these questions and explain how a biopsy fits into the broader assessment rather than presenting it as an isolated test.
A biopsy is not without some flaws. Limitations include:
In many cases, combining trichoscopy with clinical examination allows clinicians to avoid biopsy altogether. Where a biopsy is done, choosing an experienced dermatopathologist can make a substantial difference in the quality and clarity of interpretation.



